PEMETREXED Drug Patent Profile

When do Pemetrexed patents expire, and what generic alternatives are available?

Pemetrexed is a drug marketed by Actavis, Shilpa, Accord Hlthcare, Amneal, Apotex, Baxter Hlthcare Corp, Biocon Pharma, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hetero Labs Ltd Vi, Hospira, Jiangsu Hansoh Pharm, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Prinston Inc, Qilu Pharm Hainan, Reliance Life, Zydus Pharms, and Sandoz. and is included in twenty-six NDAs. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in PEMETREXED is pemetrexed ditromethamine. There are twenty-nine drug master file entries for this compound. Additional details are available on the pemetrexed ditromethamine profile page.

DrugPatentWatch^® Generic Entry Outlook for Pemetrexed

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PEMETREXED

International Patents:	1
US Patents:	1
Applicants:	21
NDAs:	26
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	1,107
Patent Applications:	3,803
Drug Prices:	Drug price information for PEMETREXED
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PEMETREXED
What excipients (inactive ingredients) are in PEMETREXED?	PEMETREXED excipients list
DailyMed Link:	PEMETREXED at DailyMed

See drug prices for PEMETREXED

Recent Clinical Trials for PEMETREXED

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	PHASE2
Intergroupe Francophone de Cancerologie Thoracique	PHASE2
Chang Chen	PHASE1

See all PEMETREXED clinical trials

Pharmacology for PEMETREXED

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for PEMETREXED

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for PEMETREXED

PEMETREXED is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nang Kuang Pharm Co	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	207352-002	May 25, 2022	AP	RX	No	No
Hospira	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	202111-001	May 25, 2022		DISCN	No	No
Zydus Pharms	PEMETREXED DISODIUM	pemetrexed disodium	POWDER;INTRAVENOUS	214073-001	May 25, 2022	AP	RX	No	No

EU/EMA Drug Approvals for PEMETREXED

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Alimta	pemetrexed	EMEA/H/C/000564Malignant pleural mesotheliomaAlimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.Non-small-cell lung cancerAlimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.	Authorised	no	no	no	2004-09-20
KRKA d.d.	Pemetrexed Krka	pemetrexed	EMEA/H/C/003958Malignant pleural mesotheliomaPemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.	Authorised	yes	no	no	2018-05-22
Menarini International Operations Luxembourg S.A.	Ciambra	pemetrexed	EMEA/H/C/003788Malignant pleural mesothelioma, , Ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma., , Non-small cell lung cancer, , Ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology., , Ciambra is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy., , Ciambra is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,	Authorised	yes	no	no	2015-12-02

International Patents for PEMETREXED

See the table below for patents covering PEMETREXED around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016151365

Supplementary Protection Certificates for PEMETREXED

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0432677	SPC/GB05/011	United Kingdom		PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
0432677	7/2005	Austria		PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920

Last updated: June 20, 2026

Market dynamics and financial trajectory for pemetrexed (Alimta): revenues, growth drivers, exclusivity, and generic/biosimilar risks

Pemetrexed (marketed as Alimta; Eli Lilly) has shifted from exclusivity-era growth to a mature oncology cash-flow profile shaped by: (1) solid dosing and combination positioning in non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), (2) competitive erosion from pemetrexed generics, and (3) cycle-of-care volatility driven by guideline updates and payer mix. Financial trajectory is dominated by global generic penetration after patent and regulatory exclusivity expiry, with incremental revenue now more dependent on branded share retention, access reforms (formulary wins), and relative uptake versus newer triplet regimens in NSCLC.

What is the current market positioning of pemetrexed (Alimta) in NSCLC and malignant pleural mesothelioma?

Pemetrexed is a cytotoxic antifolate used in combination or maintenance strategies across multiple solid-tumor settings, with the commercial center of gravity tied to NSCLC chemotherapy and MPM treatment patterns.

Where does pemetrexed fit in NSCLC treatment pathways?

Commercial uptake is linked to guideline-defined use in:

• Nonsquamous NSCLC with platinum-based chemotherapy (typically with pemetrexed + cisplatin or carboplatin depending on regimen).
• Maintenance strategies that include pemetrexed-based continuation after induction chemotherapy in eligible patients.
• Combination lines where pemetrexed has maintained a role against alternatives like immune checkpoint inhibitor (ICI) regimens and chemo-ICI hybrids, with selection influenced by biomarker status, comorbidity, and payer coverage.

Where does pemetrexed sit in malignant pleural mesothelioma care?

MPM remains a key branded anchor historically, with pemetrexed-based regimens forming the chemotherapy backbone in many treatment algorithms. Commercial durability depends on:

• Persistence of chemotherapy use in real-world MPM populations as opposed to later-line alternative regimens.
• Geographic access to pemetrexed procurement channels, including government formularies and oncology procurement frameworks.

Market dynamics that change demand month to month

• Cycle-of-care timing: revenue fluctuates with chemotherapy start rates and dosing schedules (dose reductions, interruptions, and treatment discontinuation).
• Patient mix: higher proportion of nonsquamous NSCLC and MPM cases strengthens pemetrexed demand; payer-driven regimen switching can weaken it.
• Drug budget pressure: generic conversion and price cuts in major markets compress branded and near-branded realized net pricing.

How has the financial trajectory of Alimta (pemetrexed) changed from launch-era growth to mature-market revenue?

Pemetrexed’s financial trajectory broadly follows a pattern common to cytotoxic oncology brands: strong growth during exclusivity, followed by rapid revenue compression once generic manufacturers entered and captured supply and payer preference.

What drives branded revenue under exclusivity?

During exclusivity, financial outcomes are typically driven by:

• Broad guideline inclusion and physician familiarity.
• Combination regimen share with platinum partners.
• Continuous supply reliability and oncology distribution strength.

What drives branded revenue after generic entry?

Post-entry revenue erosion is driven by:

• Formulary substitution and step therapy.
• Wholesale and payer contracting with lower-cost pemetrexed generics.
• Reduced brand promotion effectiveness as purchasing shifts to generics.
• Patient-level switching where clinicians are indifferent across equivalent pemetrexed products.

What happens to margins during generic erosion?

• Branded net price compresses due to competitive tendering.
• Eli Lilly’s opportunity shifts toward defending contracts and controlling channel supply, while manufacturers of generics compete primarily on price and manufacturing throughput.
• Oncology chemotherapy procurement can create sharp quarterly revenue impacts based on tender cycles.

When does pemetrexed lose exclusivity, and how does that affect revenue?

Loss of exclusivity impacts pemetrexed revenue in two dimensions:

1. regulatory exclusivity and patent expiry for the active drug and key formulations,
2. market exclusivity around specific indications or label expansions, which can delay or accelerate erosion depending on claim coverage and manufacturing entry pathways.

What exclusivity milestones matter most commercially?

• Patent expiry for active ingredient and core formulations: typically drives generic launch and channel switching.
• Orange Book-listed formulation and method claims: can affect whether “authorized” or “at-risk” generic entries proceed for particular strengths or presentation configurations.
• Any remaining data exclusivity on specific labeled indications: can slow label-specific uptake even if generic entry is permitted.

How generic entry translates into revenue compression

Revenue typically declines with:

• Rapid conversion to lower-priced generics once contracts renew.
• Slower switching in certain institutions if there are physician preference barriers or supply constraints.
• A lag between filing/approval and broad contracting impact.

What patents protect pemetrexed, and how do they influence market access timing?

Pemetrexed’s long-term market access is shaped by a multi-layer patent estate that usually includes:

• Active ingredient-related claims
• Composition/formulation claims tied to dosing and stabilization
• Process/manufacturing method claims
• Method-of-use claims tied to clinical regimens

Commercial leverage shifts when claims break by:

• Patent expiry
• Successful Paragraph IV challenges
• Settlements that allow earlier or later generic launch windows

What patent categories tend to matter most for chemotherapy brands?

• Formulation patents that can delay generic parity for specific presentations or strengths.
• Method-of-use or regimen patents can influence “label entry” rather than “market entry,” but both affect uptake.
• Manufacturing process patents can impact ability to scale supply or qualify product quickly.

How litigation and settlement patterns change launch probabilities

For oncology drugs, outcomes are often determined by whether:

• challengers clear all blocking patents,
• settlements carve out launch-dates by strength or indication,
• courts narrow or invalidate specific claims.

How many pemetrexed generics exist, and what is the competitive landscape?

The commercial landscape for pemetrexed is characterized by multiple generic manufacturers across major markets, with competition focused on price, supply reliability, and tender responsiveness.

Typical competitive segments

• FDA-approved generics with equivalent dosing and route: compete on price and wholesaler contracts.
• Authorized generics (if any structures exist): may smooth brand erosion but reduce branded price competition dynamics.
• Contract manufacturers and high-volume suppliers: win through manufacturing scale and distribution coverage.

How does competition differ by geography?

• U.S.: driven by FDA approval timing, Orange Book patent landscape, and payer contracting cycles.
• Europe: driven by national tender systems, price-reimbursement frameworks, and local generic penetration.
• Emerging markets: influenced by government procurement, import logistics, and local manufacturing capacity.

What is the Orange Book status of pemetrexed products?

Orange Book status drives the practical timing of generic entry by listing patents tied to:

• active ingredient
• dosage form
• method-of-use
• certain formulation or formulation-related patents

Commercial significance:

• If no listed patents remain for a specific claim set, generic entry risk falls.
• If listed patents remain, generics typically file via Paragraph IV or wait for expiry.

How strong is the patent estate for pemetrexed, and which claim types drive barriers?

For chemotherapy brands, barriers to generic entry tend to be concentrated in:

• formulation and manufacturing claims that can require reformulation or new process validation
• method-of-use claims that preserve certain labeled indications from “label-for-label” substitution
• strong composition-of-matter coverage that prevents easy design-around

Market outcome:

• When composition/formulation barriers persist after early claim challenges, generic penetration can become slower and more fragmented.
• When core barriers fall, generic substitution becomes swift across the channel.

What generic entry risks exist for pemetrexed, including at-risk launches and Paragraph IV challenges?

Generic entry risk for pemetrexed depends on whether challengers can prevail in:

• Paragraph IV litigations over listed patents
• settlement agreements that shift launch timing

Market outcome:

• At-risk launches occur when challengers assess that blocking patents are invalid or not infringed.
• If a court enjoins entry, the economic cost shifts to additional delay and sunk development.

How does pemetrexed compare with competing chemotherapy and chemo-IO regimens for revenue durability?

Pemetrexed competes indirectly with regimens where chemotherapy is combined with ICIs or replaced by alternative cytotoxics, particularly in NSCLC where practice has shifted toward immunotherapy-centric pathways.

Competitive substitution dynamics in NSCLC

• When guidelines favor chemo-IO, chemotherapy components compete on tolerability and response profiles, which can preserve pemetrexed share but reduce overall chemo usage proportion.
• Where maintenance strategies move toward immunotherapy, chemotherapy maintenance duration can compress.

Competitive substitution dynamics in MPM

MPM remains more chemotherapy-centric than many NSCLC lines, supporting relative durability of pemetrexed-based chemotherapy compared with broader NSCLC chemo substitution.

How do reimbursement, tendering, and payer policies affect pemetrexed pricing power?

Pricing power erodes as generics expand. Pemetrexed’s remaining branded leverage is tied to:

• formulary placement
• contract pricing under therapeutic interchange rules
• hospital procurement tender cycles
• local substitution regulations

Commercial signals to monitor:

• average selling price (ASP) compression in U.S. and parallel price erosion in ex-U.S. markets
• share of generics in hospital dispensing
• physician switching patterns after generic adoption

Key FDA and regulatory milestones that shape commercial outcomes for pemetrexed

Regulatory milestones determine entry windows, label expansions, and manufacturing continuity.

What FDA actions most affect market outcomes?

• Approvals of new strengths/presentations
• Label updates tied to indication expansions or regimen changes
• Manufacturing site approvals that expand supply and reduce shortages
• Generic approvals and whether they require litigation-driven timing

How regulatory status affects generics entering the market

• If FDA approvals proceed without blocked claims, generics enter sooner and shift contracting behavior.
• If label-specific barriers exist, generics may enter for limited indications, delaying full channel substitution.

What does the financial trajectory imply for near-term revenue exposure?

Near-term revenue exposure is typically dominated by:

• ongoing generic price competition
• remaining brand share retention where hospital contracting still includes branded products
• use-cycle variability in NSCLC and MPM
• channel inventory adjustments during tender cycles

In practical commercial terms:

• revenue growth is unlikely without new differentiation; outcomes hinge on competitive dynamics and contract wins
• downside risk continues from further price compression and increasing generic penetration

Key Takeaways

• Pemetrexed’s market is mature and revenue is primarily shaped by generic penetration and payer contracting, not by new clinical differentiation.
• Financial trajectory follows a typical oncology cytotoxic lifecycle: exclusivity-era growth followed by sharp branded erosion once generics enter.
• Remaining commercial value depends on branded share defense through formularies and procurement timing, plus treatment-cycle durability in MPM and selected NSCLC populations.
• Patent estate strength and Orange Book listings determine generic entry timing; once key barriers fall, channel substitution accelerates.
• Near-term revenue exposure is mainly price compression and share loss, with limited upside absent new label differentiation or significant shifts in standard-of-care.

FAQs

1. How do pemetrexed generics typically impact Alimta’s net price and ASP in the U.S.?
2. Do method-of-use patents meaningfully delay generic substitution for pemetrexed regimens?
3. Which pemetrexed indications are most sensitive to guideline shifts in NSCLC maintenance strategies?
4. How do procurement tender cycles translate into quarterly revenue swings for chemotherapy brands like Alimta?
5. What manufacturing or supply constraints most affect pemetrexed availability and payer contracting?

References

1. FDA Orange Book. “Approved Drug Products with Therapeutic Equivalence Evaluations for Pemetrexed.” (accessed 2026-06-21).
2. Eli Lilly. Alimta (pemetrexed) U.S. Prescribing Information. (accessed 2026-06-21).

DrugChatter Q&A for PEMETREXED

Inj pemetrexed 800mg price?
Pemetrexed injection price?
Pemetrexed pharmaceutical brand?
Pemetrexed wikipedia patent expiration?
Pemetrexed fda exclusivity expiration date?